Our goal is to build a drug-development and preclinical testing platform for neurodegeneration. Growth and de-risking strategies include expanding our pipeline of investigational product candidates and contract research with strategic partners.
712 North is a biopharma founded at UCSF around a novel, proprietary mitochondrial target protease crucial for neuronal survival. The target is highly validated and supported by in vivo data for Alzheimer’s disease. Knock-out of the protease can protect against neurodegeneration.
Want to learn more?
Email us, or come see us in person.
We have built a strong team of scientists and entrepreneurs to make this venture a success. Our team is complemented by mentors and advisors with expertise in drug development, drug delivery, and clinical trial design.
712 North Inc. is a Silicon Valley-style pharmaceutical company in the heart of San Francisco. We are devoted to the innovation of new therapies and drugs for rare and major neurodegenerative diseases.